

Pdx1 (*MODY4*) regulates pancreatic beta cell susceptibility to ER stress

Mira M. Sachdeva^a, Kathryn C. Claiborn^a, Cynthia Khoo^a, Juxiang Yang^a, David N. Groff^a, Raghavendra G. Mirmira^b, and Doris A. Stoffers^{a,1}

^aDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism and Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, 415 Curie Boulevard, Philadelphia, PA 19104; and ^bDepartment of Pediatrics and the Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202

Edited by Gerald I. Shulman, Howard Hughes Medical Institute/Yale University, New Haven, CT, and approved August 24, 2009 (received for review May 5, 2009)

Type 2 diabetes mellitus (T2DM) results from pancreatic β cell failure in the setting of insulin resistance. Heterozygous mutations in the gene encoding the β cell transcription factor pancreatic duodenal homeobox 1 (*Pdx1*) are associated with both T2DM and maturity onset diabetes of the young (*MODY4*), and low levels of *Pdx1* accompany β cell dysfunction in experimental models of glucotoxicity and diabetes. Here, we find that *Pdx1* is required for compensatory β cell mass expansion in response to diet-induced insulin resistance through its roles in promoting β cell survival and compensatory hypertrophy. *Pdx1*-deficient β cells show evidence of endoplasmic reticulum (ER) stress both in the complex metabolic milieu of high-fat feeding as well as in the setting of acutely reduced *Pdx1* expression in the Min6 mouse insulinoma cell line. Further, *Pdx1* deficiency enhances β cell susceptibility to ER stress-associated apoptosis. The results of high throughput expression microarray and chromatin occupancy analyses reveal that *Pdx1* regulates a broad array of genes involved in diverse functions of the ER, including proper disulfide bond formation, protein folding, and the unfolded protein response. These findings suggest that *Pdx1* deficiency leads to a failure of β cell compensation for insulin resistance at least in part by impairing critical functions of the ER.

chromatin occupancy | diabetes | gene regulation | islet compensation

The pathogenesis of type 2 diabetes reflects a dynamic interaction between environmental influences and complex genetic predisposition in which the development of insulin resistance, largely associated with obesity, is initially balanced by increased insulin production by the pancreatic β cells. In some individuals, the increased demand for insulin eventually overwhelms the capacity of the β cell to respond, resulting in progressive β cell dysfunction and overt diabetes. Indeed, β cell compensation is considered the critical determinant of whether impaired glucose tolerance will advance to frank diabetes (1). The islet compensatory response consists of an increase in both insulin secretion and β cell number. Patients with type 2 diabetes have reduced β cell volume at autopsy, underscoring the importance of β cell mass in maintaining glucose homeostasis (2). Notably, β cell failure is not limited to type 2 diabetes but rather is a common feature of most forms of diabetes, including autoimmune type 1 diabetes, ketosis-prone diabetes, and the monogenic, autosomal-dominant maturity onset diabetes of the young (*MODY*) syndromes (3).

The β cell-enriched pancreatic duodenal homeobox 1 (*Pdx1*) gene, also known as *Ipf1* (*MODY4*), encodes a transcription factor that critically regulates early pancreas formation and multiple aspects of mature β cell function, including insulin secretion, mitochondrial metabolism, and cell survival (4–6). *Pdx1* directly regulates expression of the insulin gene and other components of the glucose-stimulated insulin secretion pathway (7, 8). Reduced *Pdx1* expression in the β cell occurs in cellular models of glucose toxicity and accompanies the development of diabetes in complex genetic and environmental animal models of the disease, correlating low *Pdx1* levels with β cell failure (9–13).

Heterozygous mutations in *Pdx1* are associated with type 2 diabetes in humans, suggesting that *Pdx1* plays a role in islet compensation for insulin resistance (14, 15). This hypothesis is supported by studies using genetic mouse models of insulin resistance. In mice doubly heterozygous for the insulin receptor (*IR*) and insulin receptor substrate 1 (*IRS-1*), superimposed *Pdx1* haploinsufficiency impairs both insulin secretion and compensatory β cell mass expansion, leading to worsened glucose tolerance (16); however, in the insulin resistant *Glut4^{+/-}* model, concurrent *Pdx1* heterozygosity leads to hyperglycemia due to defects in insulin secretion with no impairment in β cell mass expansion (17). The basis for the discrepancy regarding the role of *Pdx1* in compensatory expansion of β cell mass in these genetic models of insulin resistance has not been elucidated but may involve differences in the sites and severity of insulin resistance. In particular, impaired insulin responsiveness of the β cell itself in the *IR^{+/-}/IRS-1^{+/-}* model may limit *Pdx1*-mediated compensatory β cell mass expansion. Further, these genetic models offer limited analogy to human type 2 diabetes which is rarely caused by mutations in insulin response pathways. Therefore, we sought to define the role of *Pdx1* in compensatory β cell mass expansion using a mouse model of high-fat diet (HFD)-induced insulin resistance that more closely parallels the progression to type 2 diabetes in humans.

The role of *Pdx1* as a transcription factor regulating islet compensation suggests that the identification of direct *Pdx1* transcriptional targets will offer insights into the molecular mechanisms of the islet response to insulin resistance that may be exploited therapeutically to prevent or delay the progression of diabetes. To this end, we performed high-throughput gene expression profiling and chromatin occupancy experiments in primary murine islets and Min6 mouse insulinoma cells. The results of these studies complemented the characterization of HFD-fed *Pdx1^{+/-}* mice to reveal that *Pdx1* regulates the susceptibility of pancreatic β cells to endoplasmic reticulum (ER) stress and ER stress-induced apoptosis and uncovered a broad role for *Pdx1* in transcriptional regulation relevant to ER function.

Results

***Pdx1^{+/-}* Mice Develop Diabetes in Response to HFD-Induced Insulin Resistance.** We fed *Pdx1^{+/-}* male mice and their *Pdx1^{+/+}* littermates a HFD starting at 4 weeks of age and followed them for 5 months.

Author contributions: M.M.S., K.C.C., C.K., and D.A.S. designed research; M.M.S., K.C.C., C.K., J.Y., and D.N.G. performed research; R.G.M. contributed new reagents/analytic tools; M.M.S., K.C.C., C.K., and D.A.S. analyzed data; and M.M.S. and D.A.S. wrote the paper.

Conflict of interest statement: D.A.S. is a coinventor on a patent entitled "Compositions and methods for detecting pancreatic disease" which covers the detection of *Pdx1*/*Ipf1* mutations in human disease, the royalties from which were \$0 during the last 12 months.

This article is a PNAS Direct Submission.

The array data have been deposited in the Array Express database, <http://www.ebi.ac.uk/microarray-as/ae/> (accession no. E-MTAB-134).

¹To whom correspondence should be addressed. E-mail: stoffers@mail.med.upenn.edu.

This article contains supporting information online at www.pnas.org/cgi/content/full/0904849106/DCSupplemental.




Fig. 1. *Pdx1*^{+/-} mice develop diabetes in response to HFD-induced insulin resistance. (A) Baseline glucose tolerance test and body weights of 3.5-week-old male *Pdx1*^{+/-} mice (*n* = 16) and their wild-type *Pdx1*^{+/+} littermates (*n* = 15). GTT was performed after a 6 h fast; *P* < 0.001 by ANOVA. (B) Weight gain profile of *Pdx1*^{+/-} mice and their littermate controls after randomization into HFD or normal chow (NC) groups. *, *P* < 0.05, **, *P* < 0.005 *Pdx1*^{+/+} HFD vs. NC; †, *P* < 0.05, ††, *P* < 0.005 *Pdx1*^{+/-} HFD vs. NC. (C) Insulin tolerance test after 5 months on HFD or NC (by ANOVA, *P* < 0.005 *Pdx1*^{+/+} HFD vs. NC; *P* = 0.06 *Pdx1*^{+/-} HFD vs. NC; *P* = 0.985 *Pdx1*^{+/+} HFD vs. *Pdx1*^{+/-} HFD). (D) Six-hour fasting blood glucose levels of mice 5 months in HFD or NC group. *, *P* < 0.001, *Pdx1*^{+/-} HFD vs. NC; †, *P* < 0.001, ††, *P* < 0.00001 relative to diet-matched *Pdx1*^{+/+} littermates. (E and F) IP glucose tolerance tests on mice fasted overnight after 1 month (E) and 4 months (F) on HFD or NC. In (E), *P* < 0.005 for *Pdx1*^{+/-} HFD vs. NC and *P* < 0.001 for all other pair-wise comparison groups by ANOVA. In (F), *P* < 0.0001 for all comparison groups by ANOVA. Glucose values of 600 mg/dL represent the upper limit of detection. (G) Acute insulin release in mice 3 months on HFD or NC. Plasma insulin was measured by ELISA after IP glucose injection. *, *P* < 0.05, **, *P* < 0.005 relative to time 0; †, *P* < 0.05, ††, *P* < 0.01 relative to diet-matched *Pdx1*^{+/+} littermates; #, *P* < 0.05, ##, *P* < 0.01 relative to corresponding NC controls. For (B–G), *n* = 8 mice per group, and data represent the mean ± standard error.

At baseline, body weights were comparable but *Pdx1*^{+/-} mice already displayed mild glucose intolerance (Fig. 1A). Although high-fat feeding induced similar weight gain (Fig. 1B) and an equivalent degree of insulin resistance (Fig. 1C, *P* = 0.985 by ANOVA for HFD-fed *Pdx1*^{+/+} vs. HFD-fed *Pdx1*^{+/-}) in mice of both genotypes, it caused severe hyperglycemia only in *Pdx1*^{+/-} mice, with blood glucose levels >400 mg/dL after a 6-h fast (Fig. 1D). Glucose tolerance tests revealed a greater impairment in glucose homeostasis in HF-fed *Pdx1*^{+/-} animals relative to diet-matched *Pdx1*^{+/+} littermates evident after 1 month of HF-feeding (Fig. 1E) that progressed to overt diabetes by 4 months on the HFD (Fig. 1F).

The development of diabetes in HF-fed *Pdx1*^{+/-} mice indicated a failure of *Pdx1* haploinsufficient β cells to respond appropriately to diet-induced insulin resistance. As normal islet compensation involves a combination of increased insulin secretion as well as an expansion of functional β cell mass, we first examined the acute insulin secretory response in HF- or normal chow (NC)-fed *Pdx1*^{+/-} and *Pdx1*^{+/+} littermates by measuring plasma insulin levels during glucose tolerance testing. Whereas *Pdx1*^{+/+} mice on either diet had a normal increase in insulin secretion 5 min after glucose injection, NC-fed and HF-fed *Pdx1*^{+/-} animals both exhibited an absence of first-phase insulin release (Fig. 1G). Furthermore, while the HFD induced compensatory fasting hyperinsulinemia in all mice, fasting insulin levels in HF-fed *Pdx1*^{+/-} mice were significantly lower than in HF-fed *Pdx1*^{+/+} littermates (Fig. 1G). The functional β cell defect observed in HF-fed *Pdx1*^{+/-} mice is consistent with the impaired insulin secretion described in *Pdx1*^{+/-} animals alone or in the context of genetic insulin resistance (4, 16, 17).

***Pdx1* Is Required for Compensatory β Cell Mass Expansion in Response to HFD.** While the role of *Pdx1* in functional islet compensation appears unequivocal in genetic models of insulin resistance, these models provide discrepant results regarding its role in morphological β cell compensation (16, 17). To determine whether *Pdx1* is required for normal β cell mass expansion in response to HFD-induced insulin resistance, we measured pancreatic β cell mass in *Pdx1*^{+/-} and *Pdx1*^{+/+} mice fed HFD or NC for 5 months. While the HFD stimulated a 2-fold increase in β cell mass in *Pdx1*^{+/+} controls, this did not occur in *Pdx1*^{+/-} mice (Fig. 2A and B). Therefore, in

the context of diet-induced insulin resistance, *Pdx1* is required for compensatory β cell mass expansion.

When comparing this finding with the published studies of *Pdx1* haploinsufficiency in genetic models of insulin resistance, our results thus far accorded with the *IR*^{+/-}/*IRS-1*^{+/-} model, in which the impaired β cell mass expansion in *IR*^{+/-}/*IRS-1*^{+/-}/*Pdx1*^{+/-} mice was attributed to reduced rates of β cell proliferation (16). However, surprisingly, the HFD induced a similar approximately 2-fold increase in β cell proliferation in both *Pdx1*^{+/+} and *Pdx1*^{+/-} mice as assessed by BrdU incorporation (Fig. 2C).

As we found no significant impairment in proliferation, and recent literature suggests that neogenesis does not contribute significantly to adult β cell turnover (18), we considered whether the failure to expand β cell mass in this model might be due to decreased cell survival. Indeed, HF-feeding resulted in a 4-fold increase in β cell apoptosis only in *Pdx1*^{+/-} mice (Fig. 2D). Further, although β cell hypertrophy has been suggested not to contribute to HFD-induced β cell mass expansion in mice (19), we found that *Pdx1*^{+/+} animals fed a HFD showed a significant increase in mean β cell size relative to NC-fed controls whereas HF-fed *Pdx1*^{+/-} β cells failed to exhibit this hypertrophic response (Fig. 2E). Therefore, the inability of *Pdx1*^{+/-} mice to expand β cell mass in response to diet-induced insulin resistance is due primarily to a decrease in β cell survival and a lack of compensatory hypertrophy rather than to an impairment in β cell replication.

Evidence of ER Stress in *Pdx1*-Deficient β Cells. Recent literature demonstrates that β cells of T2DM patients show increased evidence of apoptosis and endoplasmic reticulum (ER) stress (2, 20, 21). In mouse models of diet-induced obesity, HF-feeding has been linked to ER stress induction in hepatocytes and adipocytes, contributing to peripheral insulin resistance (22). Moreover, multiple lines of recent evidence suggest that HFD-induced insulin resistance might impose ER stress on the β cell and that an inability to trigger an appropriate unfolded protein response (UPR) can lead to β cell death (21, 23, 24). Given that *Pdx1* and ER function are both critical for insulin secretion and cell survival, we examined the ultrastructural appearance of the ER in β cells of HF- or NC-fed *Pdx1*^{+/+} and *Pdx1*^{+/-} mice using electron microscopy. HF-fed *Pdx1*^{+/+} β cells showed mild ER dilation relative to NC-fed controls




Fig. 2. *Pdx1* haploinsufficiency limits β cell mass expansion by decreasing β cell survival and blocking compensatory hypertrophy without impairing proliferation. (A) Representative images of insulin immunohistochemistry (brown) performed on pancreas sections from mice 5 months on either HFD or NC. (Scale bars, 50 μ m.) (B) Quantification of β cell mass ($n = 5$ –8 mice per group; *, $P < 0.05$ relative to corresponding NC controls). (C) Quantification of β cell proliferation using BrdU/insulin double immunofluorescence. $n = 4$ –6 mice per group and $>1,000$ insulin-positive cells were counted per animal; *, $P < 0.05$, **, $P < 0.005$ relative to NC controls. (D) Rates of β cell apoptosis as assessed by TUNEL. For sections containing TUNEL/insulin double positive cells, cell death was quantified by normalizing to total number of insulin positive cells ($\approx 3,000$ – $9,000$ per slide). $n = 4$ –6 mice per group; **, $P < 0.01$ relative to NC control. (E) Mean β cell size was approximated by dividing total insulin-positive area per islet by number of insulin-positive nuclei per islet. $n = 4$ –6 mice per group and 7–17 islets were analyzed per animal (**, $P < 0.001$ relative to NC control).

(Fig. 3A and B), likely reflecting the increased demand for insulin output. The ER of NC-fed *Pdx1*^{+/-} β cells was also slightly dilated compared with NC-fed *Pdx1*^{+/+} controls (Fig. 3C). However, the ER of HF-fed *Pdx1*^{+/-} β cells was severely distended compared with all other groups (Fig. 3D). This marked ER distention was specific to the *Pdx1*-expressing insulin-producing β cells, whereas the glucagon-producing alpha cells of the islet had normal, well-organized ER (Fig. 3D, left, arrow).

To confirm that the β cells of HF-fed *Pdx1*^{+/-} mice were experiencing increased ER stress, we measured expression of markers of the UPR in islets from mice of all groups. Transcript levels of the chaperone Bip after 8 weeks on either diet paralleled the pattern of ER dilation observed by electron microscopy, with higher Bip expression in HF-fed *Pdx1*^{+/+}, NC-fed *Pdx1*^{+/-}, and HF-fed *Pdx1*^{+/-} islets relative to NC-fed *Pdx1*^{+/+} controls (Fig. 3E). Increased Bip protein was also evident by immunostaining, particularly in islets of *Pdx1*^{+/-} mice fed the HFD (Fig. 3F). Further supporting the conclusion that *Pdx1* haploinsufficient β cells are more susceptible to ER stress, HF-feeding induced a 2.5-fold increase in splicing of *Xbp1*, a marker of activation of the IRE1 α arm of the UPR, only in *Pdx1*^{+/-} islets (Fig. 3G), while total *Xbp1* transcript levels remained unchanged (Fig. 3H). The specific reduction in spliced *Xbp1* levels in NC-fed *Pdx1*^{+/-} islets suggests that *Pdx1* may regulate the processing of *Xbp1* transcript.

HFD-induced insulin resistance is a complex model involving multiple metabolic abnormalities including hyperglycemia as well as increased levels of circulating free fatty acids, both of which are well-known triggers of ER stress in the β cell (11, 24). Therefore, we sought to determine whether *Pdx1* directly regulates the ER stress response in β cells, independent of other metabolic disturbances, by examining the consequences of an acute reduction in *Pdx1* expression on the UPR in the Min6 mouse insulinoma β cell line. Adenoviral shRNA-mediated knockdown of *Pdx1* in Min6

cells achieved a 60–80% reduction in *Pdx1* levels (Fig. S1) and increased *Xbp1* splicing 2 h after pharmacological induction of ER stress with either thapsigargin, which disrupts intracellular calcium homeostasis, or tunicamycin, an inhibitor of protein glycosylation (Fig. 3I). We also noted a significant reduction in stimulated Bip expression 8 h after treatment with tunicamycin (Fig. 3J). These data indicate a direct role for *Pdx1* in regulating β cell susceptibility to ER stress.

***Pdx1* Deficiency Enhances Susceptibility to ER Stress-Induced Apoptosis.** To determine whether *Pdx1* deficiency promotes ER stress-induced apoptosis, we examined several measures of β cell survival in *Pdx1*-deficient Min6 cells and *Pdx1* haploinsufficient primary β cells in vivo. First, we observed increased caspase 12 cleavage after acute reduction of *Pdx1* expression in Min6 cells (Fig. 4A). Caspase 12 is localized to the ER and has been implicated as a specific mediator of ER stress-induced apoptosis (25). Next, β cell apoptosis was directly quantified by annexin V staining and flow cytometry. We found that siRNA-mediated silencing of *Pdx1* increased apoptosis in Min6 cells, both at baseline and in the setting of ER stress induced by 1 μ M thapsigargin (Fig. 4B). Finally, we injected NC-fed *Pdx1*^{+/-} mice and their *Pdx1*^{+/+} littermates with tunicamycin to assess β cell susceptibility to ER stress-induced apoptosis in the setting of *Pdx1* deficiency in vivo. As expected, tunicamycin induced ER stress in multiple tissues, including kidney (Fig. S2). Quantification of apoptosis rates using TUNEL/insulin co-staining revealed significantly increased β cell but not acinar cell death in tunicamycin-injected NC-fed *Pdx1*^{+/-} mice compared with their *Pdx1*^{+/+} controls (Fig. 4C) with no evidence of hyperglycemia (Fig. 4D). Altogether, these data indicate a direct role for *Pdx1* in regulating β cell susceptibility to ER stress induced apoptosis.

***Pdx1* Regulates Multiple Genes Involved in ER Homeostasis and the UPR.** To identify *Pdx1* transcriptional targets involved in ER function, we performed high-throughput expression microar-

Recent literature has generated an emerging appreciation for the physiological relevance of ER stress in the β cell. We find increased evidence of ER stress in the β cells of HF-fed *Pdx1*^{+/-} mice, potentially underlying both the observed insulin secretion and cell survival defects. Islets of HF-fed, wild-type mice also showed signs of significant, albeit milder, ER stress. Although a link between HFD-imposed insulin resistance and β cell ER stress has been implied both in vitro using fatty acid treatment of β cell lines and in vivo by feeding a HFD to mice with an impairment in the PERK arm of the UPR (*Eif2s1*^{+/-tm1Rjk}), our work directly demonstrates ER stress in islets of HF-fed, wild-type animals (23, 24).

Hyperglycemia and elevated levels of circulating free fatty acids likely both contribute to β cell ER stress in the HFD-fed *Pdx1*^{+/-} model. However, our findings of UPR alterations in *Pdx1* deficient Min6 cells support a direct effect of *Pdx1* loss-of-function on susceptibility to ER stress. Further, *Pdx1* deficiency promotes ER stress-associated cell death, both in Min6 cells and in vivo after tunicamycin administration even in the absence of hyperglycemia, again implicating *Pdx1* directly. Finally, reductions in *Pdx1* expression in Min6 cells and in primary islets in vivo led to reductions in both insulin transcript and insulin content (Fig. S5). Even in the setting of HF-feeding, insulin content of *Pdx1*^{+/-} islets did not rise above that of wild-type littermates, suggesting that the increased ER stress observed in the setting of *Pdx1* deficiency occurs independently of insulin biosynthesis and supporting a model in which direct regulation of ER pathways by *Pdx1* influences susceptibility

to ER stress. We identify *Atf4* and *Wfs1* as direct transcriptional targets of *Pdx1* and a remarkable number of additional genes involved in diverse aspects of ER function as downstream of *Pdx1*, suggesting multiple molecular mechanisms whereby *Pdx1* regulates β cell susceptibility to ER stress.

Our findings uncover a broad role for *Pdx1* in maintaining ER homeostasis in the β cell, which has implications both for proper folding of insulin and for β cell susceptibility to apoptosis in the setting of an increased demand for insulin production. The association of *Pdx1* mutations with type 2 diabetes in humans and low levels of *Pdx1* with β cell dysfunction in experimental models of diabetes points to *Pdx1* regulation of ER homeostasis as a potential therapeutic target for type 2 diabetes.

Materials and Methods

Detailed methods for the use of animals and cell lines, physiological testing, morphological analyses, islet isolation, gene silencing, qPCR, chromatin immunoprecipitation, high throughput expression and promoter arrays, and statistical analyses can be found in *SI Text*.

ACKNOWLEDGMENTS. We thank K. Kaestner, M. Lazar, and M. Birnbaum for reading the manuscript, C. Wright for providing *Pdx1*^{+/-} mice, and G. Blobel for ChIP protocols. Microarrays were carried out by the Functional Genomics Core (supported by National Institutes of Health Grant DK19525). We acknowledge electron microscopy technical support from the Biomedical Imaging Core (R. Meade) and support for all other morphological analyses from G. Swain [Morphology Core (P30-DK050306)]. This work was supported by National Institutes of Health Grants P01 DK49210 and R01 DK068157 (to D.A.S.), T32-GM08216 (to M.M.S.), and R01 DK60581 (to R.G.M.).

- Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. *J Clin Invest* 116:1802–1812.
- Butler AE, et al. (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes* 52:102–110.
- Balasubramanyam A, Nalini R, Hampe CS, Maldonado M (2008) Syndromes of ketosis-prone diabetes mellitus. *Endocr Rev* 29:292–302.
- Brissova M, et al. (2002) Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. *J Biol Chem* 277:11225–11232.
- Gauthier BR, et al. (2004) Oligonucleotide microarray analysis reveals PDX1 as an essential regulator of mitochondrial metabolism in rat islets. *J Biol Chem* 279:31121–31130.
- Johnson JD, et al. (2003) Increased islet apoptosis in *Pdx1*^{+/-} mice. *J Clin Invest* 111:1147–1160.
- Ohlsson H, Karlsson K, Edlund T (1993) IPF1, a homeodomain-containing transactivator of the insulin gene. *EMBO J* 12:4251–4259.
- Chakrabarti SK, James JC, Mirmira RG (2002) Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, *Pdx1*. Importance of chromatin structure in directing promoter binding. *J Biol Chem* 277:13286–13293.
- Seufert J, Weir GC, Habener JF (1998) Differential expression of the insulin gene transcriptional repressor CCAAT/enhancer-binding protein beta and transactivator islet duodenum homeobox-1 in rat pancreatic beta cells during the development of diabetes mellitus. *J Clin Invest* 101:2528–2539.
- Zangen DH, et al. (1997) Reduced insulin, GLUT2, and IDX-1 in beta-cells after partial pancreatectomy. *Diabetes* 46:258–264.
- Wang H, Kouri G, Wollheim CB (2005) ER stress and SREBP-1 activation are implicated in beta-cell glucolipotoxicity. *J Cell Sci* 118:3905–3915.
- Gremlich S, Bonny C, Waeber G, Thorens B (1997) Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels. *J Biol Chem* 272:30261–30269.
- Ahn YB, et al. (2007) Changes in gene expression in beta cells after islet isolation and transplantation using laser-capture microdissection. *Diabetologia* 50:334–342.
- Stoffers DA, Ferrer J, Clarke WL, Habener JF (1997) Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. *Nat Genet* 17:138–139.
- Hani EH, et al. (1999) Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. *J Clin Invest* 104:R41–48.
- Kulkarni RN, et al. (2004) PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. *J Clin Invest* 114:828–836.
- Brissova M, et al. (2005) Reduced PDX-1 expression impairs islet response to insulin resistance and worsens glucose homeostasis. *Am J Physiol Endocrinol Metab* 288:E707–714.
- Dor Y, Brown J, Martinez OI, Melton DA (2004) Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. *Nature* 429:41–46.
- Hull RL, et al. (2005) Dietary-fat-induced obesity in mice results in beta cell hyperplasia but not increased insulin release: Evidence for specificity of impaired beta cell adaptation. *Diabetologia* 48:1350–1358.
- Huang CJ, et al. (2007) High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. *Diabetes* 56:2016–2027.
- Laybutt DR, et al. (2007) Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. *Diabetologia* 50:752–763.
- Ozcan U, et al. (2004) Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science* 306:457–461.
- Scheuner D, et al. (2005) Control of mRNA translation preserves endoplasmic reticulum function in beta cells and maintains glucose homeostasis. *Nat Med* 11:757–764.
- Karaskov E, et al. (2006) Chronic palmitate but not oleate exposure induces endoplasmic reticulum stress, which may contribute to INS-1 pancreatic beta-cell apoptosis. *Endocrinology* 147:3398–3407.
- Yoneda T, et al. (2001) Activation of caspase-12, an endoplasmic reticulum (ER) resident caspase, through tumor necrosis factor receptor-associated factor 2-dependent mechanism in response to the ER stress. *J Biol Chem* 276:13935–13940.
- Joe MK, et al. (2008) Crucial roles of neuronatin in insulin secretion and high glucose-induced apoptosis in pancreatic beta-cells. *Cell Signal* 20:907–915.
- Loots GG, Ovcharenko I (2004) rVISTA 2.0: Evolutionary analysis of transcription factor binding sites. *Nucleic Acids Res* 32:W217–221.
- Pagani M, et al. (2000) Endoplasmic reticulum oxidoreductin 1-beta (ERO1-beta), a human gene induced in the course of the unfolded protein response. *J Biol Chem* 275:23685–23692.
- Offield MF, et al. (1996) PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. *Development* 122:983–995.
- Zinszner H, et al. (1998) CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. *Genes Dev* 12:982–995.